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BY-NC-ND license (http://creativecomAbstract Background: Pentraxin-3 (PTX3) and soluble tumor necrosis factor (TNF)-like weak
inducer of apoptosis (sTWEAK) are new candidate prognostic markers for comorbidities and
mortality in various inflammatory diseases. Acute decompensation of cirrhosis is characterized
by acute exacerbation of chronic systemic inflammation. Recently, increased circulating PTX3
levels have been reported in nonalcoholic steatohepatitis patients and positively correlated
with disease severity. This study aims to explore serum PTX3/sTWEAK levels and their relation-
ship with clinical outcomes in cirrhotic patients with acute decompensation.
Methods: We analyzed serum PTX3/sTWEAK levels in relation to inhospital and 3-month new
clinical events and survivals in cirrhotic patients with acute decompensation.
Results: During admission, serum PTX3/sTWEAK levels were significantly higher in acute de-
compensated cirrhotic patients than controls and positively correlated with protein-energyGeneral Medicine and Gastroenterology, Department of Medicine, Taipei Veterans General Hospital,
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http://dx.doi.org/10.1016/j.jmii.201wasting (PEW), new infections, long hospital stays, high medical costs, and high mortality. Dur-
ing a 3-month follow-up, acute decompensated cirrhotic patients with high serum PTX3/
sTWEAK levels had more episodes of unplanned readmission and high 3-month mortality. On
multivariate analysis, high PTX3/sTWEAK levels and PEW were independent risk factors for high
mortality.
Conclusion: High serum PTX3/sTWEAK levels and PEW are common in cirrhotic patients with
acute decompensation. As compared with low serum PTX3 and sTWEAK cases, cirrhotic pa-
tients with high serum PTX3/sTWEAK levels a have higher probability of new severe infections,
severe sepsis, septic shock, type 1 hepatorenal syndrome, in-hospital, and 3-month follow-up
mortalities. Therefore, high serum PTX3/sTWEAK levels on hospital admission predict disease
severity and case fatality in cirrhotic patients with acute decompensation.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
A significantly higher percentage of acute decompensated
cirrhotic patients develop a bacterial infection either at the
time of admission or later during their hospitalization
compared with the general population.1 In advanced
cirrhosis, infections are increasingly recognized as major
triggers of severe systemic inflammation, renal failure,
encephalopathy, multiple organ failure, septic shock, and
high mortality.2e5 Therefore, it is important to find risk
factors for organ failure and death in order to help clini-
cians identify patients at the highest risk that may benefit
from early intensified surveillance, prophylaxis, and
therapy.6
C-reactive protein (CRP), the short pentraxin, is pri-
marily produced in the liver and its specificity as a diag-
nostic and prognostic tool for infection is limited.6e8
Accordingly, using serum CRP levels in cirrhotic patients
with compromised liver function will underestimate the
severity of acute infection. Therefore, it is crucial to find
better biomarkers for early detection of acute infection in
cirrhotic patients. Pentraxin-3 (PTX3) is produced by innate
immunity and endothelial cells in response to inflammatory
cytokines. PTX3 has been suggested as a rapid disease ac-
tivity marker for primary local inflammation.9,10 Due to
extrahepatic synthesis, PTX3 levels are believed to be an
independent indicator of disease activity produced at sites
of inflammation.11e13 PTX3 activates complement and
innate immunity, hence playing crucial roles in tissue and
vascular inflammation.9 In patients with heart failure and
chronic kidney disease, PTX3 has been reported as an
important predictive marker for adverse clinical out-
comes.14,15 A recent study suggested that a high PTX3 level
on hospitalization predicts severe sepsis and case fatalities
in patients with suspected infections.16
Tumor necrosis factor (TNF)-like weak inducer of
apoptosis (TWEAK) is a member of the TNF superfamily of
structurally related cytokines.17,18 TWEAK activates the
release of inflammatory cytokines and adhesion molecules
in inflammatory microenvironments to induce severe tissue
injury.17e19 In hemodialysis patients, high serum TWEAK
levels strongly predicted cardiovascular and all-cause
mortality.20 Protein-energy wasting (PEW) is considered asn W-C, et al., Serum pentraxin-3
te decompensated cirrhotic pati
5.12.006an independent predictor of survival in cirrhotic pa-
tients.21,22 Interestingly, elevated PTX3 is associated with
PEW in patients with chronic kidney disease and predicted
all-cause mortality.15 Additionally, sTWEAK and PTX3 are
surrogate markers of PEW that induce strong muscle
wasting.15,23 Acute decompensated cirrhotic patients with
infection are characterized by PEW, acute tissue, and
vascular inflammation. Taken together, this article aims to
assess whether serum PTX3 and sTWEAK levels are associ-
ated with differences in the severity of infection, clinical
complications, and short- and long-term mortalities in
cirrhosis.Methods
Detailed methods are provided in the supporting informa-
tion (see Supplementary material online).
Patients
All consecutive adult 108 patients admitted to our hospital
between January 2010 and June 2014 for treatment of an
acute decompensation of cirrhosis [ascites, hepatic en-
cephalopathy (HE), bacterial infection, variceal bleeding,
and hepatorenal syndrome (HRS)] were studied prospec-
tively.5,24 Inclusion criteria were age between 18 years and
80 years and hospitalization due to clinical decompensation
of cirrhosis.
Exclusion criteria were: human immunodeficiency virus
infection, previous transplantation or any other type of
immunodeficiency, steroid treatment, pituitary or adrenal
disease, hepatocellular carcinoma, severe chronic heart
[New York Heart Association (NYHA) function class III or IV]
or pulmonary disease [global initiative for chronic
obstructive lung disease (GOLD) III or IV], chronic dialysis,
acute respiratory distress syndrome, and refusal of patient
to participate. Patients or their relatives, in cases of HE,
gave written informed consent to participate in the study
which was approved by the Clinical Investigation and Ethics
Committee of Taipei Veterans General Hospital. On reso-
lution of HE, informed consent was requested from the
patients for continuation of the study.and tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
ents, Journal of Microbiology, Immunology and Infection (2016),
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trols, who visited our hospital for health check-ups and who
had no clinical or biochemical evidence of liver, renal, and
cardiovascular disease, were also included as the compar-
ison group in this study.
Serum sTWEAK and PTX3 measurements
In our study, serum CRP, tumor necrosis factor-a (TNF-a)
and interleukin-6 (IL-6), PTX3, and sTWEAK levels were
measured in all cases. Then, the serum PTX3/sTWEAK levels
were divided into 1ste4th quartiles as previously
described.14 The 1st quartile of serum PTX3 level was <
11.6 ng/mL (n Z 19); range of 2nd quartile of serum PTX3
level was 11.6e15.8 ng/mL (n Z 31); range of 3rd quartile
of serum PTX3 level was 15.8e25.9 ng/mL (n Z 35); range
of 4th quartile of serum PTX3 level was > 25.9 ng/mL
(n Z 23) whereas the 1st quartile serum sTWEAK level was
< 760 ng/mL (n Z 8); range of 2nd quartile of serum
sTWEAK level was 760e928 ng/mL (n Z 44); range of 3rd
quartile of serum sTWEAK level was 928e1748 ng/mL
(nZ 41); and the range of the 4th quartile of serum sTWEAK
level was > 1748 ng/mL (n Z 15) in our study.
The cut-off levels for high and low PTX3/sTWEAK levels
were determined by the corresponding second tertile levels
of acute decompensated cirrhotic patients. In detail, the
serum PTX3/sTWEAK levels greater than the 66
th percentile
were defined as high serum PTX3 ( 16.6 ng/mL) or sTWEAK
( 1096.7 pg/mL) group as previously suggested.20 From
ongoing studies focusing on exploring various prognostic
biomarkers at the regular outpatient department (OPD), we
enrolled another small group (n Z 48) of age and sex-
matched well-compensated cirrhotic patients with avail-
able blood samples for measurement of PTX3/sTWEAK
levels. The exclusion criteria for these well-compensated
cases were the same as our main studied group-cases with
acute decompensation.
Protein energy wasting
Protein energy wasting (PEW) was assessed using subjective
global nutritional assessment (SGNA) at the time of inclu-
sion, concurrent with the drawing of blood samples for
routine hematological, biochemical, and coagulation
studies.21,22 PEW was defined as SGNA score of > 1 (2e4),
and patients who met these criteria were grouped together
as malnourished patients. Body mass index (BMI) was
calculated as weight in kilograms divided by height in me-
ters squared.21,22
Endpoints
New clinical events (including bacterial infections, gastro-
intestinal bleeding, hepatic encephalopathy, and HRS)
developed during hospitalization and up to 3 months, but
not those diagnosed at inclusion, were included in the
analysis of clinical outcome. In-hospital and 3-month mor-
tality, causes of deaths, total length of hospital stay (LOS),
hospital medical costs, successive unplanned hospitaliza-
tion including reasons for admission, applied therapy, and
diagnosis at discharge of enrolled patients were recorded.Please cite this article in press as: Fan W-C, et al., Serum pentraxin-3
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syndrome (SIRS), severe sepsis, and septic shock] occurring
during the 3-month follow-up was also recorded.25
Hospital medical cost estimation
Hospital medical costs charged by Taiwan’s National Health
Insurance Administration (NHIA) include institutional ser-
vices, prescription drugs used, diagnostic tests carried out,
physician encounters, nursing, and other health services
costs. High medical cost is defined as > 1.5-fold of medical
cost than the average cost of low serum PTX3 and sTWEAK
group in cirrhotic patients.
Statistical analysis
Continuous variables were compared by the Student t test
or by the ManneWhitney U test when indicated. Discon-
tinuous variables were compared by the Chi-square test.
Survivals were obtained by the KaplaneMeier method and
compared using the log-rank test. Calculations were per-
formed with the SPSS version 11.0 (SPSS Inc., Chicago, IL,
USA). Differences were considered significant at p < 0.05.
Results are given as mean  standard deviation.
Results
Baseline characteristics of study population
In comparison with unrelated healthy controls, serum PTX3/
sTWEAK levels were already significantly increased in well-
compensated cirrhotic patients (Table 1). Significantly,
higher (PTX3) and (sTWEAK) were observed in acute
decompensated cirrhotic patients than control individuals
and well-compensated cirrhotic patients (Table 1). Addi-
tionally, cirrhotic patients with higher serum PTX3 (
16.6 ng/mL)/sTWEAK ( 1096.7 pg/mL) levels had a longer
length of hospital stay and more hospitalization medical
costs than their counterparts (Table 2). We found that 23 of
our 33 (70%) hepatitis B virus (HBV)- and none of our 36 (0%)
hepatitis C virus (HCV)-induced cirrhotic patients received
antiviral therapy at inclusion. Notably, serum PTX3 or
sTWEAK levels are similar between our enrolled acute
decompensated cirrhotic patients with (n Z 23) and
without (nZ 46) antiviral therapy (PTX3: 18.9  2.2 ng/mL
vs. 20.13  1.5 ng/mL; sTWEAK: 1563.39  71.86 pg/mL vs.
1487.69  55.67 pg/mL).
Serum PTX3 and sTWEAK levels are closely
correlated with PEW
Significantly, higher serum PTX3 and sTWEAK levels were
observed in acute decompensated cirrhotic patients with
PEW than their counterparts (Figure 1A). In particular, the
percentage of PEW was significantly higher in high PTX3 and
sTWEAK groups than the corresponding low PTX3 and
sTWEAK groups (Table 2). Additionally, a significant corre-
lation was noted between the PTX3 and SGNA score as well
as between the sTWEAK and SGNA score of acute decom-
pensated cirrhotic patients (Table 3).and tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
ents, Journal of Microbiology, Immunology and Infection (2016),
Table 1 Baseline characteristics of healthy controls, well-compensated cirrhotic patients, and acute decompensated cirrhotic
patients.
Healthy controls
(n Z 169)
Well-compensated
cirrhotic patients
(n Z 48)
Acute decompensated
cirrhotic patients
(n Z 108)
Male sex (%) 68 63 71
Age (y) 50.3  19 54.8  13 57.6  11
BMI (kg/m2) 25.7  3.2 23.4  2.9 21.2  6.2
Mean arterial pressure (mmHg) 121  31 ** 114  16 * 95.3  8
Heart rate (beats/min) 71  9.2 76  10.5 89.8  11.2
Hemoglobin (Hgb, g/dL) 13.8  1.2 ** 12.1  4.3 10.9  3.8
Albumin (g/dL) 3.9  2.8 * 3.4  1.9 3.1  1.5
ALT (U/L) 31  17 51  8 72  2
AST (U/L) 29  28 48  19 89  13
BUN (mg/dL) 15  3 ** 29  11 35  8
Creatinine (mg/dL) 0.6  0.5 1.1  0.2 1.3  0.4
Platelet count (103/mL) 123  40 * 90  28*** 81  32
INR for prothrombin time 1.0  0.1 1.4  0.6 1.9  0.4
PTX3 level at inclusion 7.9  1.8 ** 11.6  0.5 *,*** 19.7  3.2
sTWEAK level at inclusion 9.2  4.9 ** 549  23 *,**** 1459  215
* p < 0.05.
** p < 0.005 versus acute decompensated cirrhotic patients.
*** p < 0.01.
**** p < 0.001 versus healthy controls.
ALT Z alanine aminotransferase; AST Z asparate aminotransferase; BUN Z blood urea nitrogen; BMI Z body mass index;
INR Z international ratio; PTX3 Z long pentraxin 3; sTWEAK Z soluble TNF-like weak inducer of apoptosis.
Table 2 Clinical data of acute decompensated cirrhotic patients at inclusion.
High [PTX3]
(n Z 51)
16.6 ng/mL
Low [PTX3]
(n Z 57)
<16.6 ng/mL
High [sTWEAK]
(n Z 55)
1096.7 pg/mL
Low [sTWEAK]
(n Z 53)
< 1096.7 g/mL
Age (y) 55  10 57  8 58  4 52  16
Male sex 73 71 69 74
Protein-energy wasting (PEW) (þ), SGNA (> 1) 35 ** 13 38 ** 15
Length of hospital stay (d) 13.8  7 ** 6.3  4 14.6  5.1 ** 6.2  3.7
Hospitalization per-person medical costs (NTD) 38931  3227 ** 21025  1026 39115  2209 ** 22116  1064
Acute on liver failure 12 10 11 9
Diabetes mellitus 18 16 17 15
Ascites 66 69 69 71
Hepatic encephalopathy 30 25 29 24
Gastrointestinal bleeding 17 20 18 19
Type 1-hepatorenal syndrome (HRS) 3.4 2.8 2.5 1.9
Mean arterial pressure (mmHg) 86  12 88  16 91  11 108  7
Systemic inflammatory response syndrome 67 * 33 72 * 39
Bilirubin (mg/dL) 4.5  2.6 4.1  1.9 3.6  2.0 4.2  1.5
Prothrombin time 56  15 62  7 65  9 58  13
Creatinine (mg/dL) 1.33  0.07 1.41  1.05 1.54  1.01 1.63  0.04
Blood urea nitrogen (mg/dL) 31  8 32  7 29  11 27  14
ChildePugh score (points) 9.8  1.6 10.5  0.3 11.1  1.8 10.2  1.1
Model of end stage liver disease score (points) 19.2  4.1 18.7  3.9 19.1  4.0 17.8  2.5
IL-6 (pg/mL) 918  147 ** 249  253 1046  221 ** 263  115
TNF-a (pg/mL) 68  11.2 * 36  19 70  12 * 31  16
C-reactive protein (CRP, mg/dL) 5.61  0.1.4 * 2.3  0.9 3.7  2.3 3.9  0.9
Data are presented as % unless otherwise indicated.
* p < 0.05.
** p < 0.005 versus corresponding group.
IL-6 Z interleukin-6; NTD Z new Taiwan dollars; PTX3 Z pentraxin-3; sTWEAK Z soluble TNF-like weak inducer; TNF-a Z tumor ne-
crosis factor-a.
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Figure 1. (A) Serum PTX3/sTWEAK levels in acute decompensated cirrhotic patients with and without protein energy wasting
(PEW); (B) clinical event free percentage in acute decompensated cirrhotic patients with low and high PTX3; (C) sTWEAKlevels
during 3-month follow-up period; and (D) relative risk of presence of severe clinical events (severe sepsis, septic shock, and type 1
HRS) in the 3-month follow-up period in acute decompensated cirrhotic patients with 1st, 2nd, 3rd, and 4th quartile of serum PTX3/
sTWEAK levels [PTX3:10.8 ng/mL (nZ 21), 13.7 ng/mL (nZ 36), 16.6 ng/mL (nZ 30), 19.5 ng/mL (nZ 21); sTWEAK:371.7 pg/mL
(n Z 19), 734.2 pg/mL (n Z 34), 1096.7 pg/mL (n Z 33), 1459.2 pg/mL (n Z 22)]. PEW is defined as SGNA score >1.
HRSZ hepatorenal syndrome; PTX3Z pentraxin-3; SGNAZ subjective global nutritional assessment; sTWEAKZ soluble TNF-like
weak inducer of apoptosis; Q Z quartile.
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correlated with high levels of inflammatory
mediators
Serum IL-6 and TNF-a levels were significantly higher in
acute decompensated cirrhotic patients belonging to high
PTX3 and sTWEAK groups than their counterparts (Table 2).Table 3 Pearson correlation coefficients (r) between serum pen
acute decompensated cirrhotic patients.
Between PTX3 & relevant parameters
Pearson’s r p
sTWEAK 0.16 0.022 P
CRP 0.41 0.041 C
IL-6 0.34 0.038 I
TNF-a 0.59 0.015 T
SGNA score 0.67 0.029 S
CRPZ C-reactive protein; IL-6 Z interleukin-6; PTX3 Z pent
sTWEAK Z soluble TNF-like weak inducer; TNF-a Z tumor necrosis f
Please cite this article in press as: Fan W-C, et al., Serum pentraxin-3
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http://dx.doi.org/10.1016/j.jmii.2015.12.006Significantly, a positive correlation was noted between
PTX3 and IL-6 as well as between sTWEAK and IL-6 (Table 3).
Nonetheless, a significantly higher serum CRP level was only
noted in the high PTX3 group than the low PTX3 group.
Meanwhile, the PTX3 significantly positively correlated with
serum TNF-a and CRP levels (Table 3).
Differentially, the difference of serum CRP levels be-
tween high sTWEAK and low sTWEAK groups did not reachtraxin-3 (PTX3) and sTWEAK levels and relevant parameters in
Between sTWEAK & relevant parameters
Pearson’s r p
TX3 0.16 0.022
RP 0.16 0.09
L-6 0.25 0.007
NF-a 0.35 0.06
GNA score 0.78 0.016
raxin-3; SGNA Z subjective global nutritional assessment;
actor-a.
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Figure 2. Comparison of serum (A) PTX3 and (B) sTWEAK levels of acute decompensated cirrhotic patients with controls ac-
cording to the severity of infection. * p < 0.01 versus control; ** p < 0.001 versus sequential elevation with increased severity of
infection. PTX3 Z pentraxin-3; sTWEAK Z soluble TNF-like weak inducer of apoptosis.
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patients. The sTWEAK was not significantly correlated with
serum TNF-a and CRP levels (Table 3).Association between serum PTX3/sTWEAK levels
and severity of infection during admission
More acute decompensated cirrhotic patients with high
serum PTX3 and sTWEAK levels met the criteria of SIRS for
inclusion in our study (Table 2). In subgroup analysis ac-
cording to the infection status, significantly higher PTX3
and sTWEAK levels were presented in acute decom-
pensated cirrhotic patients with SIRS or concurrent infec-
tion than healthy controls; whereas serum PTX3 levels
were not different between acute decompensated
cirrhotic patients without SIRS or infection and healthy
controls (Figure 2A). In acute decompensated cirrhotic
patients, more severe infection, such as sepsis, severe
sepsis, and septic shock, was associated with higher serum
PTX3 levels (Figure 2A). By contrast, even without the
presence of SIRS or concurrent infection, the serum
sTWEAK level was significantly increased in acute decom-
pensated cirrhotic patients than healthy controls. How-
ever, the sequential elevation of sTWEAK levels along with
the increased infectious severity was not apparent in our
study group (Figure 2B).Please cite this article in press as: Fan W-C, et al., Serum pentraxin-3
predict severity of infections in acute decompensated cirrhotic pati
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and new clinical events
Compared with acute decompensated cirrhotic patients
with lower serum PTX3 levels (< 16.6 ng/mL), those with a
higher PTX3 level suffered from significantly more events of
bacterial infection, including spontaneous bacterial peri-
tonitis (SBP), severe sepsis, septic shock, and type 1-HRS
during hospitalization (Table 4). The incidence of such
clinical events at 3 months of follow-up was also signifi-
cantly higher in acute decompensated cirrhotic patients
with higher serum levels of PTX3. Likewise, acute decom-
pensated cirrhotic patients with higher serum sTWEAK
levels ( 1096.7 pg/mL) had significantly more incidence of
bacterial infection, SBP, severe sepsis, and septic shock
during hospitalization. At 3 months of follow-up, the inci-
dence of such clinical events was significantly higher in
acute decompensated cirrhotic patients with higher serum
sTWEAK level, as well (Table 4). Significantly, a higher
clinical event-free rate was noted in the low serum PTX3/
sTWEAK groups than its corresponding groups after
3 months follow-up (Figures 1B and 1C).
In subgroup analysis according to the respective quar-
tiles of serum PTX3 and sTWEAK levels, the relative risk for
clinical events, including severe sepsis, septic shock, and
type 1-HRS, at 3 months of follow-up was significantly
higher in acute decompensated cirrhotic patients with theand tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
ents, Journal of Microbiology, Immunology and Infection (2016),
Table 4 New clinical events (which were not present at admission) of acute decompensated cirrhotic patients with low and
high serum PTX3/sTWEAK levels.
High PTX3 (n Z 51)
 16.6 ng/mL
Low PTX3 (n Z 57)
< 16.6 ng/mL
High sTWEAK (n Z 55)
 1096.7 pg/mL
Low sTWEAK (n Z 53)
< 1096.7 g/mL
During hospitalization
Variceal bleeding 10 4 8 3
Bacterial infection 36.3 ** 13.7 30.6 ** 12.1
eSpontaneous bacterial
peritonitis (SBP)
14 * 5 21 ** 6
Severe sepsis 17 ** 3 12 7
Septic shock 15 * 7 21 * 11
Type 1-HRS 9 * 4 10 8
At 3 months follow-up
Variceal bleeding 11 7 10 8
Bacterial infection 29 * 18 34 ** 13
eSBP 16 ** 8 23 * 11
Severe Sepsis 8.7 ** 0.5 4.1 ** 1.3
Septic shock 11 * 5 15 * 9
Type 1-HRS 13 * 6 17 ** 8
Data are presented as %.
* p < 0.05.
** p < 0.005 versus corresponding group.
HRSZ hepatorenal syndrome; PTX3Z pentraxin-3; SBPZ spontaneous bacterial peritonitis; sTWEAKZ soluble TNF-like weak inducer.
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those with the lowest (1st quartile) corresponding levels
(Figure 1D).
Risk factors at inclusion for new clinical
complications and mortality of acute
decompensated cirrhotic patients
On univariate analysis, high PTX3 and sTWEAK levels,
presence of PEW, septic shock, and hyponatremia were
significantly related to unplanned readmission and high
mortality during the 3-month follow-up (Table 5).
On multivariate analysis, both high serum PTX3 and
sTWEAK levels were associated with increased risks of in-
hospital and 3-month mortality (Table 6). Besides, PEW
increased the risks of mortality, unplanned readmission,
and high medical costs during hospitalization.
Discussion
In response to bacterial infection, cirrhotic patients have
pronounced inflammatory response with elevated systemic
pyrogenic cytokines IL-6 and TNF-a concentrations.26 As a
consequence, SIRS can be found in up to 67% of cirrhotic
patients with bacterial infections compared with 37% of
patients without, making sepsis a common complication of
advanced cirrhosis.27 Therefore, a higher percentage of our
cirrhotic patients complicated with SIRS and sepsis have
high serum PTX3 and sTWEAK levels. Clinically, a higher
percentage of decompensated cirrhotic patients met SIRS
criteria due to hyperdynamic circulation-related tachy-
cardia or tense ascites-related hyperventilation. However,
these patients might be finally classified as having sterile
SIRS if negative for any inflammation and infection afterPlease cite this article in press as: Fan W-C, et al., Serum pentraxin-3
predict severity of infections in acute decompensated cirrhotic pati
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detect early conditions that are serious rather than sterile
SIRS in order to give great beneficial management to pa-
tients at the right time point.
In cirrhotic patients, serum concentrations of inflam-
matory marker IL-6 and CRP are positively correlated with
risk of organ failure and increased short-term mortal-
ity.7,27,28 Interestingly, a significant correlation was noted
between serum IL-6 and CRP levels supported previous re-
ports of IL-6 as a potent inducer of CRP.29 In acute
decompensated cirrhotic patients with suspected infection,
high serum IL-6 and TNF-a had been found to correlate with
increased in-hospital episodes of bacterial infection, short-
term reinfection, and 1-year mortality.30 However, neither
IL-6 nor TNF-a determine the mortality of our acute
decompensated cirrhotic patients. These discrepancy re-
sults might come from different studied groups between
previous studies and our current study.30
In multivariate analysis, the ChildePugh and model for
end stage liver disease (MELD) scores did not predict mor-
tality in our study. These results indicated that factors
other than severity of cirrhosis contributed to the mortality
of acute decompensated cirrhotic patients. In fact, a pre-
vious study reported that MELD score is not a perfect
prognostic tool and some decompensated cirrhotic patents
may be misclassified as a low risk group.31
Hyponatremia is reported to be associated with
increased severity of complications and risk of mortality in
cirrhotic patients.32 Therefore, it is reasonable to find in
our study that hyponatremia is associated with high 3-
month mortality in our acute decompensated cirrhotic
patients.
In cirrhosis, PEW is due to chronic inflammation,
reduction in oral intake (for various causes), increased
protein catabolism, insufficient synthesis, malabsorption,and tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
ents, Journal of Microbiology, Immunology and Infection (2016),
Table 5 Univariate analysis of risk factors at inclusion for various clinical complications of acute decompensated cirrhotic
patients (n Z 108).
HR 95% CI p HR 95% CI p
In hospital mortality 3-mo mortality
(1) High PTX3 ( 16.6 ng/mL) 3.28 1.43e1.23 0.003 (1) High [PTX3 ( 16.6 ng/mL) 2.71 2.1e3.11 0.0014
(2) High sTWEAK ( 1096.7 pg/mL) 4.18 1.08e1.42 0.002 (2) High [sTWEAK] ( 1096.7 pg/mL) 2.81 1.6e3.45 0.003
(3) High MELD score (point > 10) 0.96 0.54e1.12 0.09 (3) High MELD score (point>10) 0.99 0.9e1.64 0.095
(4) High ChildePugh score (> 6) 0.825 0.66e0.95 0.41 (4) High ChildePugh score (> 6) 0.71 0.68e1.35 0.16
(5) Septic shock (þ) 1.008 1.001e1.01 0.07 (5) Septic shock (þ) 0.82 0.71e1.15 0.004
(6) Hyponatremia [sodium
(< 130 mEq/L)]
0.73 0.65e1.12 0.078 (6) Hyponatremia [sodium
(< 130 mEq/L)]
2.83 2.6e3.1 0.002
(7) Protein energy wasting PEW (þ) 2.19 1.03e1.25 0.002 (7) PEW (þ) 3.15 2.9e3.6 0.01
(8) Type 1 hepatorenal syndrome
[HRS (þ)]
0.69 0.53e0.98 0.001 (8) Type 1 HRS 0.66 0.53e1.2 0.07
High hospitalization medical cost 3-mo unplanned readmission rates
(1) High PTX3 ( 16.6 ng/mL) 2.49 1.8e3.4 0.002 (1) High PTX3 ( 16.6 ng/mL) 0.89 0.79e1.34 0.08
(2) High sTWEAK ( 1096.7 pg/mL) 0.78 0.6e1.8 0.098 (2) High sTWEAK (1096.7 pg/mL) 5.11 3.6e5.8 0.004
(3) High MELD score (point > 10) 0.91 0.85e1.63 0.069 (3) High MELD score (point >10) 1.1 0.82e1.49 0.085
(4) High ChildePugh score (> 6) 0.83 0.52e1.56 0.08 (4) High ChildePugh score (> 6) 0.81 0.93e1.12 0.069
(5) Septic shock (þ) 2.79 0.61e1.03 0.003 (5) Septic shock (þ) 0.69 0.52e0.89 0.05
(6) Hyponatremia
[sodium (< 130 mEq/L)]
0.83 0.75-1.12 0.08 (6) Hyponatremia [sodium
(< 130 mEq/L)]
1.07 1.1e1.62 0.004
(7) PEW (þ) 1.67 1.4e2.1 0.008 (7) PEW (þ) 4.93 3.8e5.1 0.001
(8) Type 1 HRS 3.21 1.96e3.82 0.002 (8) Type 1 HRS 0.67 0.5e0.99 0.071
High hospitalization medical cost was defined as > 1.5fold of medical cost than the average cost of low serum PTX3 and sTWEAK group.
CI Z confidence internals; HR Z hazard ratio; MELD Z Model For End-Stage Liver Disease; PEW Z protein energy wasting;
PTX3 Z pentraxin-3; sTWEAK Z soluble TNF-like weak inducer of apoptosis.
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Worse PEW can lead to ascites, encephalopathy, hep-
atorenal syndrome, septic complications, poorer quality
life, a reduced life span, and death in cirrhosis.21,22,33 Using
clinical information to determine nutritional status, SGNA
score accounting for recent weight loss or gain, has been
successfully applied to cirrhotic patients to predict the
outcome after liver transplantation.21 In our cirrhotic pa-
tients with acute decompensation, a strong correlation was
noted between SGNA and serum sTWEAK levels. It has been
reported that TWEAK induces proinflammatory cytokine
production.34 Furthermore, proinflammatory cytokines
stimulate the PTX3 production.
35 In other words, the regu-
lation of serum PTX3 production by sTWEAK is mediated by
proinflammatory cytokines. This cross-interaction between
sTWEAK and PTX3 was further confirmed by simultaneous
elevations of serum sTWEAK and PTX3 in patients with
chronic kidney disease36 and acute decompensated
cirrhotic patients in our study.
Concomitant renal failure is a major determinant for
mortality of admitted cirrhotic patients.37 Cirrhotic pa-
tients with acute kidney injury (AKI) develop type 1-HRS,
which reduces survival presumably by superimposing
inflammation.38
Aggressive treatment with high-dose intravenous albu-
min substitution for type 1-HRS seems a legitimate
approach to reduce mortality of admitted cirrhotic pa-
tients. Estimation of medical costs in our study is based on
the public connected database of our medical center with
National Health Insurance Administration (NHIA) which in-
cludes length of hospital stay and medical costs. In Taiwan,
albumin is expensive and most cirrhotic patients cannotPlease cite this article in press as: Fan W-C, et al., Serum pentraxin-3
predict severity of infections in acute decompensated cirrhotic pati
http://dx.doi.org/10.1016/j.jmii.2015.12.006afford the economic burden for adequate doses of intra-
venous albumin infusion for type 1-HRS. For admitted
cirrhotic patients with the diagnosis of type 1-HRS, NHIA
pays for their albumin-related medical costs. Undoubtedly,
the hospitalization medical costs for cirrhotic patients with
type 1-HRS must be remarkably higher than those without
type 1-HRS. Therefore, it is reasonable to find in our study
that cirrhotic patients with type 1-HRS have high mortality
and hospitalization medical costs.
In either HBV- or HCV-induced cirrhotic patients, our
initial comparison data indicated that presence of antiviral
therapy at inclusion did not modify the serum PTX3/sTWEAK
levels of enrolled acute decompensated cirrhotic patients.
However, the small and imbalance of the group size (nZ 23
vs. n Z 46) between our acute decompensated cirrhotic
patients with and without using oral nucleotide analogues
might affect the evaluation of the impact of antiviral
therapy on the serum PTX3/sTWEAK levels. Therefore,
further well-designed studies with large and balance sam-
ple size is mandatory to elucidate the effect of antiviral
therapy on the serum PTX3/sTWEAK levels of acute
decompensated cirrhotic patients.
In our study, with a single determination of serum PTX3
and sTWEAK levels, we cannot take into account any vari-
ation that may have occurred over time. However, this is
not a major limitation because other inflammation and
laboratory markers were measured only once in this study.
Uusitalo-Seppa¨la¨ et al16 reported the role of high serum
PTX3 level in emergency room patients with suspected in-
fections whereas our study reported the role of high serum
PTX3 and sTWEAK levels in admitted acute decompensated
cirrhotic patients. Uusitalo-Seppa¨la¨ et al16 defined severeand tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
ents, Journal of Microbiology, Immunology and Infection (2016),
Table 6 Multivariate analysis of risk factors at inclusion
for various clinical complications of acute decompensated
cirrhotic patients (n Z 108).
HR 95% CI p
In-hospital mortality
(1) High PTX3 ( 16.6 ng/mL) 3.94 2.9e4.5 0.002
(2) High sTWEAK ( 1096.7 pg/mL) 4.75 3.4e5.7 0.023
(3) Protein energy wasting
[PEW (þ)]
2.31 2.1e3.1 0.004
High hospitalization medical cost
(1) High PTX3 ( 16.6 ng/mL) 2.41 1.7e3.8 0.008
(2) Septic shock (þ) 3.1 2.9e4.1 0.005
(3) PEW (þ) 2.48 2.1e2.9 0.003
(4) Type 1 HRS 3.7 3.4e4.2 0.002
3-month mortality
(1) High PTX3 ( 16.6 ng/mL) 3.52 2.2e4.61 0.0022
(2) High sTWEAK ( 1096.7 pg/mL) 3.26 2.3e3.8 0.0041
(3) Hyponatremia [sodium
(< 130 mEq/L)]
2.91 2.6e3.8 0.007
(4) PEW (þ) 4.0 3.5e4.5 0.03
3-mo unplanned readmission rates
(1) High sTWEAK ( 1096.7 pg/mL) 5.12 3.2e6.5 0.0016
(2) PEW (þ) 5.12 4.8e5.9 0.005
CI Z confidence internals; HR Z hazard ratio;
HRS Z hepatorenal syndrome; PEW Z protein energy wasting;
PTX3 Z pentraxin-3; sTWEAK Z soluble TNF-like weak inducer
of apoptosis.
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study included severe sepsis and septic shock. The end-
points of Uusitalo-Seppa¨la¨ et al16 study are 28-day mortal-
ity and severe sepsis whereas our studying end points are
new in-hospital clinical events, in-hospital and 3-month
mortality, total length of hospital stay (LOS), high hospi-
talization medical costs, and unplanned readmission rates.
Conclusively, the novelties raised from this study include
high serum PTX3 and sTWEAK levels are associated with
PEW, high hospitalization medical costs, and mortality in
cirrhotic patients with acute decompensation. Additionally,
high serum sTWEAK levels and presence of PEW contributed
to the high incidence of unplanned readmission rates in
acute decompensated cirrhotic patients. Therefore, mea-
surement of serum PTX3 and sTWEAK levels provide a new
strategy to more aggressive treatments for high risk groups.
Therefore, infection prevention (vaccinations, hygiene,
and nutrition), antimicrobial deescalation strategies, and
surveillance for early signs of organ dysfunction are
required to reduce the burden associated with new clinical
events and mortality in admitted high-risk cirrhotic patients
with acute decompensation.
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